Johnson & Johnson begins Phase 3 COVID-19 vaccine candidate trial in SA

Johnson & Johnson’s Phase 3 trial of its COVID-19 vaccine candidate has commenced in South Africa. The first South African ENSEMBLE participants were dosed last week. The study is also on-going in the United States, Brazil, Chile, Colombia and Argentina. Ludovic de Beaucoudrey, the Medical Affairs Director at Janssen South Africa joins CNBC Africa for more.

Tue Nov 10 2020 | 17:55:49 GMT+0000 (Coordinated Universal Time)


Get the best of CNBC Africa sent straight to your inbox with breaking business news, insights and updates from experts across the continent. Sign up here.